Novo Nordisk A/S (NYSE:NVO) Shares Bought by Annex Advisory Services LLC

Annex Advisory Services LLC lifted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 4.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,052 shares of the company’s stock after buying an additional 219 shares during the period. Annex Advisory Services LLC’s holdings in Novo Nordisk A/S were worth $435,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in NVO. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Novo Nordisk A/S during the 2nd quarter worth $25,000. Daiwa Securities Group Inc. acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth $28,000. Capital Performance Advisors LLP acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth $42,000. Carolina Wealth Advisors LLC acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth $48,000. Finally, M&R Capital Management Inc. increased its holdings in shares of Novo Nordisk A/S by 260.5% during the 3rd quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock worth $49,000 after buying an additional 297 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $78.74 on Tuesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The firm has a 50-day moving average of $97.76 and a two-hundred day moving average of $116.89. The stock has a market cap of $353.33 billion, a P/E ratio of 25.48, a PEG ratio of 0.92 and a beta of 0.45. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15.

Wall Street Analyst Weigh In

NVO has been the subject of a number of research analyst reports. BMO Capital Markets dropped their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Buy” and a consensus price target of $140.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.